Modulate Bio

Executive Summary

Modulate Bio is a preclinical-stage biotechnology company developing novel small molecule GABA-A positive allosteric modulators (PAMs) for neurological disorders. Its platform aims to deliver differentiated PAMs with improved efficacy and reduced side effects compared to existing treatments. The company's initial pipeline targets high-need conditions such as Essential Tremor, epilepsy, and anxiety. Founded in 2021 and headquartered in San Francisco, Modulate Bio is privately held and has not yet disclosed its total fundraising or valuation. As a preclinical entity, the company's progress depends on advancing its lead candidates through IND-enabling studies and into clinical development.

Upcoming Catalysts (preview)

• Q2 2027IND Filing for Lead Candidate in Essential Tremor30% success
• Q4 2026Preclinical Data Presentation at Major Neurology Conference60% success
• Q2 2026Series A Funding Announcement70% success